Laboratory medicine: An essential partner in the care of cancer patients

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 10, 2011, Pages 1575-1578

  Melichar, Bohuslav ^a   Plebani, Mario ^b  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CRIZOTINIB; ERLOTINIB; GEFITINIB; MESOTHELIN; MICRORNA; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE PHOSPHATASE; TRASTUZUMAB; ZINC;

BIOCHEMISTRY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; EARLY DIAGNOSIS; EARLY INTERVENTION; HISTOLOGY; HUMAN; LABORATORY TEST; LUNG NON SMALL CELL CANCER; MALIGNANT MESOTHELIOMA; METASTASIS; MULTIDRUG RESISTANCE; PANCREAS CANCER; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; TREATMENT PLANNING; TUMOR LOCALIZATION; ZINC BLOOD LEVEL;

CLINICAL LABORATORY TECHNIQUES; EARLY DIAGNOSIS; HUMANS; NEOPLASMS; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 80054941885     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.244     Document Type: Review

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA-A Cancer J Clin 2011;61:69-90.
2. Pasche B, Absher D. Whole-genome sequencing: A step closer to personalized medicine. JAMA 2011;305:1596-7.
3. Albert H, Santos S, Battaglia E, Brito M, Monteiro C, Bagrel D. Differential expression of CDC25 phosphatases splice variants in human breast cancer cells. Clin Chem Lab Med 2011;49: 1707-14.
4. Wang F, Chen L, Ding W, Wang J, Luo L, Cong H, et al. Serum APRIL, a potential tumor marker in pancreatic cancer. Clin Chem Lab Med 2011;49:1715-9.
5. Yamada S, Tabata C, Tabata R, Fukuoka K, Nakano T. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma. Clin Chem Lab Med 2011;49:1721-6.
6. Lianidou ES, Markou A. Circulating tumor cells as emerging tumor biomarkers in breast cancer. Clin Chem Lab Med 2011;49:1579-90.
7. Markou A, Liang Y, Lianidou E. Prognostic, therapeutic and diagnostic potencial of microRNAs in non-small cell lung cancer. Clin Chem Lab Med 2011;49:1591-603.
8. Trape J, Filella X, Alsina-Donadeu M, Juan-Pereira L, Bosch-Ferrer A, Rigo-Bonnin R. Increased plasma concentrations of tumour markers in the absence of neoplasia. Clin Chem Lab Med 2011;49:1605-20.
9. Darago A, Sapota A, Matych J, Nasiadek M, Skrzypinska-Gavrysiak M, Kilanowicz A. The correlation between zinc and insulin-like growth factor 1 (IGF-1). its binding protein (IGBF-3) and prostate-specific antigen (PSA) in prostate cancer. Clin Chem Lab Med 2011;49:1699-705.
10. Plebani M, Melichar B. ROMA or death: Advances in epithelial ovarian cancer diagnosis. Clin Chem Lab Med 2011;49:443-5.
11. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
12. Kim HR, Lee CH, Kim YW, Han SK, Shim YS, Yim JJ. Increased CA 19-9 level in patients without malignant disease. Clin Chem Lab Med 2009;47:750-4.
13. Finne P, Finne R, Bangma C, Hugosson J, Hakama M, Auvinen A, et al. Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening. Int J Cancer 2004;111:310-5. (Pubitemid 38924712)
14. Melichar B, Jandik P, Malir F, Vavrova J, Bures J, Mergancova J, et al. Association between renal tubular cell dysfunction and increased urinary zinc excretion in cancer patients. Scand J Clin Lab Inv 1995;55:149-52.
15. Yamauchi H, Stearns V, Hayes DF. When is tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:2334-56. (Pubitemid 32366985)
16. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
17. Hurwitz H, Febrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42. (Pubitemid 38702844)
18. Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-celllung cancer. N Engl J Med 2005;353:123-32. (Pubitemid 41058344)
19. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620-5. (Pubitemid 351264357)
20. Melichar B. How can second-line therapy for renal cell carcinoma help to define an overall management strategy? Oncology 2009;77:82-91.
21. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
22. Weiss L. Inefficiency of metastasis from colorectal carcinomas. Relationship to local therapy for hepatic metastasis. Cancer Treat Res 1994;69:1-11.
23. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated nonsmall-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 2008;372:1809-18.
24. Kwak EL, Bang YJ, Camidge R, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-smallcell lung cancer. N Engl J Med 2010;363:1693-703.
25. Melichar B, Solichová D, Freedman RS. Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. Int J Gynecol Cancer 2006;16:240-52.
26. Melichar B, Dvorak J, Hyspler R, Zadak Z. Intestinal permeability in the assessment of intestinal toxicity of cytotoxic agents. Chemotherapy 2005;51:336-8. (Pubitemid 41546709)
27. van Vliet MJ, Tissing WJ, Rings EH, Koetse HA, Stellaard F, Kamps WA, et al. Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients. Pediatr Blood Cancer 2009;53:1188-94.
28. Bacher U, Schnittger S, Haferlach C, Haferlach T. Molecular diagnostics in acute leukemias. Clin Chem Lab Med 2009;47: 1333-41.
29. Saussoy P, Vaeman JL, Druez V, Deneys V, Straetmans N, Cornu G, et al. Expresion of lineage markers using real-time quantitative polymerase chain reaction (RT-qPCR) in normal and in leukemia bone marrow. Clin Chem Lab Med 2009;47:419-26.
30. Matsushita H, Yamamoto M, Tsuboi K, Masukawa A, Arakawa S, Asai S, et al. A novel aberrant form of e13a2 BCR-ABL1 transcript in chronic myelogenous leukemia undetectable with the standarized real-time quantitative polymerase chain reaction from the Europe Against Cancer Program. Clin Chem Lab Med 2009;47:885-7.